Birth Weight Linked to Risk of Certain Pediatric Cancers
Birth weight may be associated with the risk of certain pediatric cancers, a new study suggests.
Diagnosis & Disease Information
Mitochondrial DNA Fraction Breaks Linked to Increased Risk of NHL
Patients who have more mitochondrial DNA fraction breaks have a higher risk of developing non-Hodgkin lymphoma, according to new research.
Risk of tMDS/AML After Common Lymphoid Neoplasms
Survivors of common lymphoid neoplasms have an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, data suggest.
Carcinogens Found at Nuclear Missile Base After Cancer Cases Prompt Investigation
An investigation into cancer cases linked to a nuclear missile base revealed unsafe levels of polychlorinated biphenyls.
ASCO 2023: Lymphoma Research Could Change Practice
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
IT and IV Methotrexate Produce Similar CNS Outcomes in DLBCL
Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.
Epkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma
Epkinly (epcoritamab-bysp) is approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy.
Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
Four or More CT Scans in Childhood Linked to Increased Risk of Cancer
Exposure to 4 or more CT scans before the age of 18 is associated with an increased risk of intracranial tumors, leukemia, and lymphoma, a study suggests.
Polivy Combination Therapy Approved for Previously Untreated DLBCL
Polivy plus R-CHP is approved for the first-line treatment of patients with DLBCL NOS or HGBL who have an IPI score of 2 or greater.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...